Catheter Precision, Inc. reports acquiring 2,941,176 shares of Volato Group, Inc. common stock. The filing states the shares were acquired pursuant to a Securities Purchase Agreement dated June 7, 2026 with the purchase closing on June 18, 2026. The reporting person beneficially owns 2,941,176 shares, representing 7.5% of the class based on the issuer's statement that 39,336,982 shares were outstanding after the private placement.
The Schedule 13G lists sole voting and dispositive power over the reported shares in the name of Catheter Precision, Inc. and is signed by the issuer's Chief Financial Officer on June 26, 2026.
Positive
None.
Negative
None.
Insights
Acquisition disclosed: private placement closed June 18, 2026 for 2,941,176 shares.
The filing documents a private placement purchase governed by a Securities Purchase Agreement dated June 7, 2026 and closed on June 18, 2026, giving Catheter Precision sole voting and dispositive power over 2,941,176 shares.
Impact depends on future holder actions and any related lock-up or resale restrictions; subsequent filings may disclose transferability or resale plans.
Holding equals 7.5% of post-transaction outstanding shares as reported by the issuer.
The ownership percentage is calculated from the issuer's statement that 39,336,982 shares were outstanding after the private placement; the 7.5% figure follows directly from those values.
Shareholders may look for additional disclosures in follow-up filings about any lock-up, registration rights, or resale mechanics tied to the private placement.
Key Figures
Shares acquired:2,941,176 sharesPercent of class:7.5%Shares outstanding (post-issuance):39,336,982 shares
"Item 1. Name of issuer: Volato Group, Inc. — filing type shown on cover"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Securities Purchase Agreementfinancial
"acquired pursuant to a Securities Purchase Agreement, dated as of June 7, 2026"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
beneficially ownslegal
"Catheter Precision, Inc. acquired and beneficially owns 2,941,176 shares"
Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.
What did Catheter Precision disclose about SOAR ownership?
Catheter Precision disclosed it beneficially owns 2,941,176 shares of Volato Group common stock as of June 18, 2026. The filing states the shares were acquired under a Securities Purchase Agreement dated June 7, 2026 and closed on June 18, 2026.
What percentage of Volato Group (SOAR) does the 2,941,176 shares represent?
The filing reports the position represents 7.5% of the class. This percentage is based on the issuer's statement that 39,336,982 shares were outstanding after the private placement in which these shares were issued.
When did the purchase of SOAR shares close according to the filing?
The purchase closing occurred on June 18, 2026. The Securities Purchase Agreement governing the acquisition is dated June 7, 2026, per the Schedule 13G disclosure incorporated in Item 4(a).
Who holds voting and dispositive power over the disclosed shares?
The Schedule 13G states that Catheter Precision, Inc. has sole voting power and sole dispositive power over the reported 2,941,176 shares, as reflected in the cover page rows incorporated by reference.
Where did the outstanding share count come from?
The outstanding share count of 39,336,982 shares is cited from the Issuer's Form S-3 Registration Statement filed on June 18, 2026, which the reporting person used to calculate the 7.5% ownership figure.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Volato Group, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
74349W302
(CUSIP Number)
06/18/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
74349W302
1
Names of Reporting Persons
Catheter Precision, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,941,176.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,941,176.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,941,176.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.5 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Volato Group, Inc.
(b)
Address of issuer's principal executive offices:
1954 AIRPORT ROAD, SUITE 124, CHAMBLEE, GEORGIA, 30341.
Item 2.
(a)
Name of person filing:
Catheter Precision, Inc.
(b)
Address or principal business office or, if none, residence:
1670 Highway 160 West, Suite 205, Fort Mill, SC 29708
(c)
Citizenship:
Delaware corporation
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP Number(s):
74349W302
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Reference is hereby made to Rows 5?9 and 11 of the cover page of this Schedule 13G, which are incorporated herein by reference. As of June 18, 2026, Catheter Precision, Inc. (the "Reporting Person") acquired and beneficially owns 2,941,176 shares (the "Shares") of common stock, par value $0.0001 per share, of Volato Group, Inc. (NYSE American: SOAR) (the "Issuer"). The Shares were acquired by the Reporting Person pursuant to a Securities Purchase Agreement, dated as of June 7, 2026, by and between the Issuer and the Reporting Person (the "Purchase Agreement"), with the closing of the purchase occurring on June 18, 2026.
The calculation of the percentage of beneficial ownership in Row 11 of the cover page of this Schedule 13G was derived from the Issuer's Form S-3 Registration Statement filed with the Securities and Exchange Commission on June 18, 2026, in which the Issuer stated that 39,336,982 shares of its common stock were outstanding after giving effect to the issuance of the Shares sold in the private placement of which the Reporting Person's purchase was a part.
(b)
Percent of class:
The information set forth in Item 4(a) herein is hereby incorporated by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information set forth in Item 4(a) herein is hereby incorporated by reference.
(ii) Shared power to vote or to direct the vote:
The information set forth in Item 4(a) herein is hereby incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information set forth in Item 4(a) herein is hereby incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information set forth in Item 4(a) herein is hereby incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
